公开(公告)号：US20140271453A1

公开(公告)日：2014-09-18

申请号：US13804639

申请日：2013-03-14

Applicant: Abbott Laboratories

Inventor： Barry L. Dowell ,  Philip M. Hemken

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N2800/52

Abstract: Provided are methods of diagnosing lung cancer, particularly at an early stage, such as stage I, by detecting the presence and/or amount of at least four biomarkers of lung cancer in a sample from a subject as well as determining the number of smoking pack years for the subject. The methods and biomarkers may be used to develop an accurate prognosis for a patient having lung cancer or suspected of having lung cancer or accurately diagnose a subject having or suspected of having lung cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for lung cancer treatment therapy.

Abstract translation: 提供了通过检测来自受试者的样品中至少四种肺癌生物标志物的存在和/或量的确定来诊断肺癌的方法，特别是在早期阶段，例如I期，以及确定吸烟包数 年的主题。 方法和生物标志物可用于为患有肺癌或怀疑患有肺癌或准确诊断具有或疑似患有肺癌的受试者的患者准确预测。 方法和生物标志物可用于鉴定和/或分类患者作为肺癌治疗治疗的候选者。

公开(公告)号：US20170089889A1

公开(公告)日：2017-03-30

申请号：US15283828

申请日：2016-10-03

Applicant: Abbott Laboratories ,  Abbott Japan Co. Ltd.

Inventor： Toru Yoshimura ,  Kenju Fujita ,  Barry L. Dowell

IPC: G01N33/53 ,  G01N33/86 ,  G01N33/574

CPC classification number: G01N33/5306 ,  G01N33/57423 ,  G01N33/86 ,  G01N2333/5758

Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample.By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.

公开(公告)号：US09459248B2

公开(公告)日：2016-10-04

申请号：US14295116

申请日：2014-06-03

Applicant: Abbott Laboratories

Inventor： Toru Yoshimura ,  Kenju Fujita ,  Barry L. Dowell

IPC: G01N33/86 ,  G01N33/53 ,  G01N33/574

CPC classification number: G01N33/5306 ,  G01N33/57423 ,  G01N33/86 ,  G01N2333/5758

Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.

Abstract translation: 通过提高已知在生物样品中不稳定的ProGRP的稳定性来提供更方便和更准确的测定ProGRP的方法。 通过使用血液凝固因子未活化的状态下的血液样品作为样品，可以抑制ProGRP的降解，能够长时间存储样品，提高准确度 一个测定。

公开(公告)号：US20140271621A1

公开(公告)日：2014-09-18

申请号：US13828319

申请日：2013-03-14

Applicant: Abbott Laboratories

Inventor： Philip M. Hemken ,  Barry L. Dowell ,  Gerard J. Davis

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N2333/70596

Abstract: Disclosed herein are methods of diagnosing pancreatic cancer in a patient by detecting the presence and/or amount of at least three biomarkers of pancreatic cancer in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having cancer or suspected of having pancreatic cancer, or to accurately diagnose a patient having, or suspected of having pancreatic cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a cancer therapy.

Abstract translation: 本文公开了通过检测来自患者的样品中至少三种胰腺癌生物标志物的存在和/或量来诊断患者胰腺癌的方法。 方法和生物标志物可用于为具有癌症或疑似患有胰腺癌的患者准确预测，或准确地诊断具有胰腺癌或怀疑患有胰腺癌的患者。 方法和生物标志物可用于鉴定和/或分类患者作为癌症治疗的候选物。